SCHEMBL21497366

SCHEMBL21497366

CC(C)(F)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD11B1 P28845 1/20 0.46
CYP19A1 P11511 8/20 0.45
LMNA P02545 1/20 0.44
CYP2A6 P11509 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HIF1A Q16665 1/20 0.44
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
CHRNA4 P43681 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497773 0.85 HSD11B1 (0.43) MEN1KMT2AHSD11B1LMNATSHR
SCHEMBL23116738 0.83 MEN1 (0.56) MEN1KMT2ACYP19A1LMNACYP2A6
SCHEMBL29092067 0.79 MEN1 (0.65) MEN1KMT2AHSD11B1CYP19A1LMNA
SCHEMBL29091903 0.79 MEN1 (0.65) MEN1KMT2AHSD11B1CYP19A1LMNA
SCHEMBL25071163 0.79 MEN1 (0.52) MEN1KMT2ACYP19A1LMNACYP2A6
SCHEMBL29091899 0.79 MEN1 (0.65) MEN1KMT2AHSD11B1CYP19A1LMNA
SCHEMBL809832 0.77 LMNA (0.50) MEN1KMT2ACYP19A1LMNACYP2A6
SCHEMBL16277011 0.77 TSHR (0.55) MEN1KMT2AHSD11B1LMNATSHR
SCHEMBL1538386 0.77 MEN1 (0.62) MEN1KMT2ACYP19A1LMNACYP2A6
SCHEMBL13379568 0.77 CYP19A1 (0.67) MEN1KMT2ACYP19A1LMNACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450286-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2019-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450286-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD MEN1 4044/4885KMT2A 4666/4885HSD11B1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.